Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Under a Creative Commons license
open access
Keywords
Rucaparib
PARP inhibitor
Ovarian carcinoma
Somatic, germline BRCA mutation
Cited by (0)
- 1
Dr. Bell-McGuinn's current affiliation is Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA, but the current work was completed during her time with Memorial Sloan Kettering Cancer Center.
© 2017 The Authors. Published by Elsevier Inc.